| Literature DB >> 28486433 |
Mark J La Guardia1, Erika D Schreder2, Nancy Uding3, Robert C Hale4.
Abstract
Inhalation of halogenated flame-retardants (HFRs) released from consumer products is an important route of exposure. However, not all airborne HFRs are respirable, and thus interact with vascular membranes within the gas exchange (alveolar) region of the lung. HFRs associated with large (>4 µm), inhalable airborne particulates are trapped on the mucosal lining of the respiratory tract and then are expelled or swallowed. The latter may contribute to internal exposure via desorption from particles in the digestive tract. Exposures may also be underestimated if personal activities that re-suspend particles into the breathing zone are not taken into account. Here, samples were collected using personal air samplers, clipped to the participants' shirt collars (n = 18). We observed that the larger, inhalable air particulates carried the bulk (>92%) of HFRs. HFRs detected included those removed from commerce (i.e., polybrominated diphenyl ethers (Penta-BDEs: BDE-47, -85, -100, -99, and -153)), their replacements; e.g., 2-ethylhexyl 2,3,4,5-tetrabromobenzoate (TBB or EH-TBB); bis(2-ethylhexyl) 3,4,5,6-tetrabromophthalate (TBPH or BEH-TEBP) and long-produced chlorinated organophosphate-FRs (ClOPFRs): tris(2-chloroethyl)phosphate (TCEP), tris(1-chloro-2-propyl)phosphate (TCPP or TCIPP), and tris(1,3-dichloro-2-propyl)phosphate (TDCPP or TDCIPP). Our findings suggest estimates relying on a single exposure route, i.e., alveolar gas exchange, may not accurately estimate HFR internal dosage, as they ignore contributions from larger inhalable particulates that enter the digestive tract. Consideration of the fate and bioavailability of these larger particulates resulted in higher dosage estimates for HFRs with log Koa < 12 (i.e., Penta-BDEs and ClOPFRs) and lower estimates for those with log Koa > 12 (i.e., TBB and TBPH) compared to the alveolar route exposure alone. Of those HFRs examined, the most significant effect was the lower estimate by 41% for TBPH. The bulk of TBPH uptake from inhaled particles was estimated to be through the digestive tract, with lower bioavailability. We compared inhalation exposure estimates to chronic oral reference doses (RfDs) established by several regulatory agencies. The U.S. Environmental Protection Agency (EPA) RfD levels for several HFRs are considered outdated; however, BDE-99 levels exceeded those suggested by the Dutch National Institute for Public Health and the Environment (RIVM) by up to 26 times. These findings indicate that contributions and bioavailability of respirable and inhalable airborne particulates should both be considered in future risk assessments.Entities:
Keywords: bioavailability; flame retardants; human exposure; indoor air quality; particle size; polyurethane
Mesh:
Substances:
Year: 2017 PMID: 28486433 PMCID: PMC5451958 DOI: 10.3390/ijerph14050507
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Normalized contributions of various halogenated flame-retardant (HFR) classes to total HFRs (>4 µm + <4 µm), inhalable (>4 µm), and respirable (<4 µm) air particulates within each indoor environment. ClOPFRs, chlorinated organophosphate-FRs; TBB, 2-ethylhexyl 2,3,4,5-tetrabromobenzoate; TBPH, bis(2-ethylhexyl) 3,4,5,6-tetrabromophthalate; penta-BDE, pentabromodiphenyl ether.
Halogenated flame retardants (HFRs) inhalable (>4 µm) and respirable (<4 µm) air particulate fraction concentrations (ng·m−3) of each indoor environment.
| 1 Gymnasiums (n = 4) | 1 Coaches’ Residences (n = 4) | 2 Residences/Offices (n = 10) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inhalable (>4 µm) | Respirable (<4 µm) | Inhalable (>4 µm) | Respirable (<4 µm) | Inhalable (>4 µm) | Respirable (<4 µm) | |||||||
| HFRs | Range (%RD) | Mean 3 | Range (%RD) | Mean 3 | Range (%RD) | Mean 3 | Range (%RD) | Mean 3 | Range (%RD) | Mean 3 | Range (%RD) | Mean 3 |
| BDE-47 | 10.1–82.7 (100%) | 33.0 | nd–5.70 (75%) | 3.06 | 0.20–2.30 (100%) | 1.45 | nd–8.50 (75%) | 3.34 | nd–1.17 (40%) | 0.23 | nd–1.39 (40%) | 0.22 |
| BDE-85 | 1.50–3.00 (100%) | 2.18 | nd (0%) | 0.05 | nd–2.00 (25%) | 0.54 | nd (0%) | 0.05 | nd (0%) | 0.05 | nd (0%) | 0.05 |
| BDE-100 | 4.40–15.4 (100%) | 8.03 | 0.60–5.50 (100%) | 2.38 | 0.50–1.90 (100%) | 1.35 | nd–1.60 (75%) | 1.04 | nd–0.19 (20%) | 0.07 | nd–1.02 (40%) | 0.32 |
| BDE-99 | 18.5–58.5 (100%) | 35.4 | nd–9.60 (75%) | 5.54 | nd–4.30 (50%) | 1.23 | nd–11.1 (50%) | 3.10 | nd–0.39 (50%) | 0.17 | nd–1.59 (70%) | 0.55 |
| BDE-153 | 1.30–6.10 (100%) | 3.90 | nd–6.70 (50%) | 1.95 | nd–0.70 (50%) | 0.28 | nd–3.00 (50%) | 1.15 | nd (0%) | 0.05 | nd (0%) | 0.05 |
| Penta-BDE | 36.9–164 (100%) | 82.5 | 1.80–20.7 (100%) | 13.0 | 3.50–7.10 (100%) | 4.84 | nd–24.1 (75%) | 8.68 | nd–1.54 (70%) | 0.57 | nd–3.74 (70%) | 1.19 |
| ∑Penta-BDE 4 | 95.5 | 13.5 | 1.76 | |||||||||
| TBB | 46.4–220 (100%) | 143 | nd–20.2 (75%) | 11.4 | 2.60–55.4 (100%) | 22.0 | nd–55.2 (75%) | 21.4 | nd–23.3 (30%) | 3.23 | nd–18.4 (40%) | 2.99 |
| TBPH | 4.90–71.9 (100%) | 34.3 | nd–12.8 (75%) | 5.41 | nd–18.3 (75%) | 8.61 | nd–18.6 (50%) | 6.93 | nd–25.6 (20%) | 2.97 | nd–3.44 (50%) | 0.57 |
| TBB + TBPH | 51.3–184 (100%) | 178 | nd–31.0 (75%) | 16.8 | 2.60–73.7 (100%) | 30.6 | nd–73.8 (75%) | 28.3 | nd–48.9 (30%) | 6.20 | nd–21.9 (50%) | 3.56 |
| ∑TBB + TBPH 4 | 195 | 58.9 | 9.76 | |||||||||
| TCEP | nd (0%) | 0.05 | nd (0%) | 0.05 | nd (0%) | 0.05 | nd (0%) | 0.05 | nd–77.8 (89%) | 19.1 | nd (0%) | 0.75 |
| TCPP | 136–525 (100%) | 266 | nd (0%) | 0.05 | 209–1360 (100%) | 536 | nd (0%) | 0.05 | 16.0-1180 (100%) | 371 | nd–28.6 (60%) | 12.3 |
| TDCPP | 125–397 (100%) | 244 | 32.0–36.5 (100%) | 34.3 | 32.0–69.2 (100%) | 50.1 | nd–26.4 (25%) | 6.64 | nd–82.2 (33%) | 19.1 | nd–20.9 (50%) | 4.97 |
| ClOPFRs | 376–650 (100%) | 510 | 32.0–36.5 (100%) | 34.4 | 241–1420 (100%) | 585 | nd–26.4 (25%) | 6.74 | 61.1–1180 (100%) | 410 | nd–34.4 (80%) | 18.0 |
| ∑ClOPFRs 4 | 544 | 592 | 428 | |||||||||
| HFRs | 608–888 (100%) | 771 | 33.8–83.0 (100%) | 64.2 | 272–1500 (100%) | 620 | nd–124 (75%) | 43.8 | 61.5–1180 (100%) | 417 | 5.80–37.8 (100%) | 22.7 |
| ∑HFRs 4 | 835 | 664 | 440 | |||||||||
1 La Guardia, M.J.; R. C. Hale 2015 [24]. Halogenated flame-retardant concentrations in settled dust, respirable and inhalable particulates and polyurethane foam at gymnastic training facilities and residences. Environ. Int. 79, 106–114. 2 Schreder, E. D.; N. Uding; M. J. La Guardia 2016 [23]. Inhalation a significant route for chlorinated organophosphate flame retardants. Chemosphere 64, 181–186. 3 Values reported as non-detect (nd) were replaced with ½ of the reported detection limit when calculating mean values for statistic evaluation. 4 Sum of the inhalable + respirable air particulate fractions. %RD = % rate of detection.
Figure 2HFR concentrations (ng·m−3) of total (>4 µm + <4 µm), inhalable (>4 µm), and respirable (<4 µm) air particulates within each indoor environment.
Daily inhalation exposure dose by alveoli fraction (D) and alveoli plus digestive tract (D) (ng·kg−1·bw·d−1) and their ratio (D).
| Gymnasiums (n = 4) | Coaches’ Residences | Residences/Offices (n = 10) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Analytes | Mean (n = 3) | |||||||||
| BDE-47 | 6.18 | 6.21 | 1.00 | 0.82 | 1.01 | 1.23 | 0.08 | 0.09 | 1.13 | 1.12 |
| BDE-85 | 0.38 | 0.33 | 0.87 | 0.10 | 0.09 | 0.90 | 0.02 | 0.02 | 1.00 | 0.92 |
| BDE-100 | 1.78 | 1.70 | 0.96 | 0.41 | 0.43 | 1.05 | 0.07 | 0.08 | 1.14 | 1.05 |
| BDE-99 | 7.02 | 6.53 | 0.93 | 0.74 | 0.89 | 1.20 | 0.12 | 0.15 | 1.25 | 1.13 |
| BDE-153 | 1.00 | 0.94 | 0.94 | 0.25 | 0.30 | 1.20 | 0.02 | 0.02 | 1.00 | 1.05 |
| Penta-BDEs | 16.4 | 15.7 | 0.96 | 2.32 | 2.72 | 1.17 | 0.31 | 0.36 | 1.16 | 1.10 |
| TBB | 26.5 | 18.6 | 0.70 | 7.44 | 7.36 | 0.99 | 1.07 | 1.05 | 0.98 | 0.89 |
| TBPH | 6.81 | 3.27 | 0.48 | 2.66 | 2.10 | 0.79 | 0.61 | 0.31 | 0.51 | 0.59 |
| TBB + TBPH | 33.3 | 21.9 | 0.66 | 10.1 | 9.45 | 0.94 | 1.67 | 1.35 | 0.81 | 0.80 |
| TCEP | 0.26 | 0.31 | 1.19 | 0.26 | 0.31 | 1.19 | 3.40 | 3.66 | 1.08 | 1.15 |
| TCPP | 45.7 | 49.4 | 1.08 | 92.0 | 99.4 | 1.08 | 65.7 | 71.5 | 1.09 | 1.08 |
| TDCPP | 47.7 | 54.1 | 1.13 | 9.82 | 11.1 | 1.13 | 4.13 | 4.76 | 1.15 | 1.14 |
| ClOPFRs | 93.7 | 104 | 1.11 | 102 | 111 | 1.09 | 73.3 | 79.9 | 1.09 | 1.10 |
| 1∑HFRs | 143 | 141 | 0.99 | 115 | 123 | 1.07 | 75.2 | 81.6 | 1.09 | 1.05 |
1 ∑HFRs = Penta-BDEs + TBB + TBPH + ClOPFRs.
Figure 3Association of daily inhalation dose exposure comparisons (D) with log octanol-air partitioning coefficient (K). D = ∑respirable + inhalable fraction (Equation (5)). D = alveoli fraction (Equation (2)). Regression analysis, curvilinear relationship (p = 0.007).